Beijing Targets Ownership Transfers in Biopharma Deals
China has moved to redraw the boundary around foreign access to its biomedical innovation base. A draft update to the country’s export blacklist would ban foreign acquisitions of certain proprietary cell and gene therapy platforms, small interfering RNA siRNA platforms and pathogen gain-of-function platforms, while also restricting full transfer of drug target identification and verification technologies in cell and gene therapy and siRNA to overseas entities.
The policy reaches beyond individual molecules and into the reusable technology stacks that can generate multiple programs. In practical terms, Beijing is trying to separate ownership of the engine from the sale of the output. For global buyers, that means the most strategically valuable Chinese assets may no longer be the easiest to purchase outright.
One sentence captures the shift: platform ownership is moving under tighter state control.
Licensing Remains Open While Ownership Faces New Scrutiny
The draft does not amount to a blanket shutdown of China-related biopharma business development. Out-licensing agreements, along with the use of know-how to provide outsourced research and manufacturing services, fall outside the proposed ban. Drug target identification and verification technology can generally still be out-licensed, and those transactions would typically be approved rather than barred.
That distinction matters because much of the Western appetite for Chinese assets has centered on licensing rather than acquisition. U.S. and European drugmakers, along with venture investors, have mostly sought access to specific compounds or to discovery platforms that can identify new molecules, not full ownership of the underlying technology base. In that model, the Chinese company keeps the platform, the foreign partner gets development rights, and both sides share the downstream economics through royalties, milestones and regional commercialization rights.
The draft policy appears calibrated to preserve that commercial flow while drawing a harder line around outright transfer of core capabilities. Beijing’s stated aim is to keep key proprietary technologies within China’s borders while still permitting orderly international collaboration around its biopharma sector.
Deal Flow Has Been Tilting Toward China’s Technology Base
China’s drug regulators say foreign transactions involving Chinese biotech assets reached $120 billion as of August this year, a 36% increase from the prior year. That figure reflects how quickly Chinese biomedicine has become a global source of assets and technologies rather than only a manufacturing base.
Yet the new rules may have a narrower real-world footprint than the headline suggests. Aaron Gu, a partner at Chinese law firm Han Kun who focuses on healthcare and life sciences, characterized the draft as regulating transfers while leaving licensing unconstrained. His assessment fits the structure of recent deals, where ownership transfer has been relatively rare compared with licensing.
PharmCube data show that as of July 1, only five of 121 cross-border Chinese biopharma out-licensing deals this year involved ownership transfer. That is a small slice of the broader market and helps explain why the draft, despite its assertive tone, may leave most transactions intact.
Gracell’s CAR-T Platform Shows Where the New Line Would Land
AstraZeneca’s $1 billion acquisition of Gracell Biotechnologies would likely have been caught by the proposed rule. Gracell developed the FasTCAR platform for making CAR-T cells, and the 2023 transaction was widely viewed as the first full acquisition of a Chinese biotech by a major pharmaceutical company.
The proposed restriction would make that kind of deal much harder to repeat. By targeting platform-level acquisitions, Beijing is signaling that the intellectual capital behind iterative drug discovery and cell engineering deserves different treatment from a single-asset license. In cell and gene therapy especially, the platform often carries more long-term value than any one candidate, because the same system can be reused across multiple indications and programs.
For buyers, the commercial implication is straightforward: if the state controls the platform, the foreign company may still be able to license a molecule, but it may no longer be able to buy the core operating system that created it.
National Security and Industrial Retention Drive the Policy
The government’s rationale is not limited to economics. For pathogen-related technologies, the spokesperson for China’s Ministry of Commerce cited national security concerns. For the rest of the policy, the justification is more industrial than defensive: Beijing wants to support what it calls orderly international collaboration while preventing the wholesale migration of critical capabilities overseas.
That framing echoes remarks from a senior Chinese biopharma executive who said authorities were concerned about companies using China’s resources to build strong research engines and then selling the entire enterprise abroad. The same executive described a preference for partnership structures over outright divestiture, because licensing leaves the Chinese company in control while still generating royalties and milestone payments. Foreign buyers can develop the asset abroad; the Chinese owner keeps the platform and the domestic rights.
This is a policy built around retained sovereignty over innovation capacity. It also reflects a simple economic calculation: China wants the foreign exchange and the scientific prestige that come from global deals, but not at the price of losing its most reusable technologies.
A Narrower Rule Than Market Rumors Feared
When rumors surfaced in May, the proposed blacklist was said to extend far more broadly, including multispecific antibodies, antibody-drug conjugates and protein degraders. The published draft is materially narrower than those market fears.
Gu described it as significantly better than expectations because it excludes the deal structures that have become standard across biopharma. The market had braced for a sweeping hit to cross-border dealmaking, yet the draft instead preserves the core architecture of current licensing practice. That leaves foreign companies with a path to Chinese innovation, but with less room to take home the platform itself.
Comments on the proposal are open until Nov. 15. Until the revised export control catalogue is formally enacted, any transfer of technology within the regulated scope must be registered with the Ministry of Commerce.
U.S. Pressure Is Building on the Other Side of the Pacific
The policy shift comes as Washington intensifies scrutiny of Chinese biotech transactions. Representative John Moolenaar and Representative Debbie Dingell have introduced the Biotech Investment National Security Act, a measure aimed at placing Chinese biopharma deals under additional review. The bill has not advanced in Congress, but it reflects the same strategic logic that is now shaping Beijing’s own response.
At the Treasury Department, which would be responsible for carrying out any new U.S. restrictions, draft rules are expected to preserve the ability of American companies to pursue most licensing deals with Chinese firms. That would leave both sides with a familiar tension: governments are tightening oversight of ownership, while preserving room for the kinds of cross-border agreements that keep drug discovery moving.
For now, the most consequential question is not whether Chinese science will continue to reach global partners. It will. The more immediate issue is which side will be allowed to own the platform when the collaboration begins.